Pressure BioSciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

Schedule of Disaggregation of Revenue


In thousands of US dollars ($)	Year Ended December 31,
Primary geographical markets	2021		2020
North America		1,179		844
Europe		289		88
Asia		534		289
		2,002		1,221

	Year Ended December 31,
Major products/services lines	2021		2020
Hardware		1,104		568
Consumables		274		205
Contract research services		268		193
Agrochem Products		29		-
Sample preparation accessories		140		116
Technical support/extended service contracts		119		96
Shipping and handling		51		29
Other		17		14
		2,002		1,221

	Year Ended December 31,
Timing of revenue recognition	2021		2020
Transferred at a point in time		1,674		978
Transferred over time		328		243
		2,002		1,221

Schedule of Contract Balances

Contract balances

Schedule of Contract Balances

In thousands of US dollars ($)	December 31, 2021		December 31, 2020
Receivables, which are included in ‘Accounts Receivable’		155		131
Contract liabilities (deferred revenue)		41		67

Schedule of Future Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.

In thousands of US dollars ($)		2022				2023				Total
Extended warranty service			37				4				41

Schedule of Inventories

Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows:

Schedule of Inventories

	2021			2020
Raw materials	$	296,892		$	217,682
Finished goods		1,193,158			717,581
Inventory reserve		(342,496	)		(342,496	)
Total	$	1,147,554		$	592,767

Schedule of Customer Concentration Risk Percentage

The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31:

	2021			2020
Top Five Customers		44	%		33	%
Federal Agencies		6	%		4	%

The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31:

	2021			2020
Top Five Customers		82	%		89	%
Federal Agencies		5	%		10	%

Schedule of Computation of Loss Per Share

	2021			2020
Numerator:
Net loss attributable to common shareholders	$	(22,685,459	)	$	(17,584,710	)

Denominator for basic and diluted loss per share:
Weighted average common shares outstanding		6,636,523			3,304,187

Loss per common share - basic and diluted	$	(3.42	)	$	(5.32	)

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31:

	2021		2020
Stock options		1,333,101		1,355,901
Convertible debt		5,232,118		4,474,868
Common stock warrants		16,207,108		14,434,702
Convertible preferred stock:
Series D Convertible Preferred		25,000		25,000
Series G Convertible Preferred		26,857		26,857
Series H Convertible Preferred		33,334		33,334
Series H2 Convertible Preferred		70,000		70,000
Series J Convertible Preferred		115,267		115,267
Series K Convertible Preferred		229,334		229,334
Series AA Convertible Preferred		8,649,000		8,043,000
		31,921,119		28,808,263

Summary of Assumptions for Grants of Stock Options

The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2021:

Assumptions	CEO, other Officers and Employees
Expected life		6.0	(yrs)
Expected volatility		155.02	%
Risk-free interest rate		0.62	%
Forfeiture rate		5.00	%
Expected dividend yield		0.0	%

Schedule of Stock Based Compensation Expense

We recognized stock-based compensation expense of $254,615 and $488,792 for the years ended December 31, 2021 and 2020, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying consolidated statements of operations for the years ended December 31:

	2021		2020
Research and development	$	128,094	$	141,202
Selling and marketing		22,233		34,142
General and administrative		104,288		313,448
Total stock-based compensation expense	$	254,615	$	488,792

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2021:

			Fair value measurements at December 31, 2021 using:
	December 31, 2021		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Equity Securities	$	59,976	$	59,976		-		-
Total Financial Assets	$	59,976	$	59,976	$	-	$	-

The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2020:

			Fair value measurements at December 31, 2020 using:
	December 31, 2020		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Equity Securities		517,001		517,001		-		-
Total Financial Assets	$	517,001	$	517,001	$	-	$	-